Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians

  • The KAP Co-op program gives eligible therapists the ability to provide ketamine-assisted psychotherapy (KAP) to their patients at Field Trip Health Centers utilizing Field Trip’s medical teams for screening, prescribing and administration of ketamine.
  • Training programs will provide both didactic and experiential training to therapists and medical professionals who wish to learn about KAP.
  • Therapists who complete Field Trip’s training programs will automatically become eligible to join the KAP Co-op program.

TORONTO, Aug. 31, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, is pleased to announce the launch of “KAP Co-op”, a program that enables eligible independent psychedelic therapists to provide ketamine-assisted psychotherapy (and, in the future, other legal, psychedelic-assisted therapies) at its Field Trip Health centers. Field Trip is also pleased to announce the launch of training programs designed to provide interested psychotherapists or other qualified mental health professionals and clinicians with access to best-in-class training on KAP.

KAP Co-op Program

Under the KAP Co-op Program, independent therapists who are experienced at providing psychedelic-assisted therapies, or who completed approved training programs through providers including MAPS, Fluence, The Ketamine Training Center and the California Institute for Integral Studies (CIIS), amongst others, are eligible to become a co-operative therapist with Field Trip (“Co-op Therapists”).

Once approved, Co-op Therapists will have access to Field Trip’s world class centers for psychedelic therapies and other resources from Field Trip to provide KAP to their own private practice clients (“Co-op Clients”).

Co-op Clients will be able to access Field Trip’s medical teams for the screening, prescribing and administration/dispensation of ketamine, while continuing to receive all preparation and integration therapy from their existing therapist.

The cost of the medical screening and ketamine administration/dispensation at a Field Trip Health center for Co-op Clients will be available for an introductory price of $400 for a limited period. The cost of the preparation and integration therapy will be established directly between the Co-op Client and the Co-op Therapist as part of their existing therapeutic relationship within the therapist’s private practice.

“The launch of the KAP Co-op Program extends Field Trip’s presence to a whole new population of therapists and their clients who want to have the Field Trip experience and access our world class Field Trip Health centers,” said Hannan Fleiman, Field Trip’s President. “Now, instead of operating in parallel to existing client-therapist relationships, Field Trip is working on a truly complementary and co-operative basis to the incredible work all psychedelic therapists are doing with their clients.”

Training Programs

Field Trip’s training programs will provide a blend of didactic and experiential training for the delivery of KAP, and will be provided over the course of a weekend (Friday – Sunday). Topics covered in the training programs will include: preparation for psychedelic therapy, techniques for guiding a psychedelic experience, and integration of insights from a psychedelic experience.

The first session of Field Trip’s therapist training program will take place on the weekend of October 8, 2021 in Seattle, WA, and will cost $1,200 USD. Future sessions will be announced at a later time and will be held at Field Trip’s various Field Trip Health center locations.

“Many therapists are eager to get practical, hands-on experience with psychedelic-assisted therapies so they can confidently start offering these powerful modalities to their clients,” said Dr. Ryan Yermus, Field Trip’s Chief Clinical Officer. “Presently, however, the options available for training are limited and are either cost prohibitive, infrequent, long or do not include hands-on training. With the launch of Field Trip’s training programs, we are making training for therapists accessible and affordable. But what is even more exciting is with the launch of our KAP Co-operative Program, therapists will be able to quickly put that training to use.”

“Therapists are on the frontline of the global mental health crisis. And everyday more evidence confirms that the best tools we have to address this crisis are psychedelic-assisted therapies,” said Ronan Levy, Field Trip’s Executive Chairman. “The best thing we can be doing right now is to equip an army of therapists with what they need to deliver these powerful therapies. And that’s exactly what Field Trip is doing. Through our training programs and our KAP Co-op Program, any qualified therapist that wants to provide psychedelic-assisted therapies will have access to the training, facilities and medical resources they need to do so.”

“I genuinely believe that in 20 years we might look back and see that the launch of these programs, along with the incredible progress we are making in advancing the science and understanding of psychedelic molecules such as FT-104, marked a turning point in the mental health crisis we are battling,” he added.

Therapists and clinicians interested in participating in KAP Co-op or Field Trip’s training programs should send an indication of interest to coop@fieldtriphealth.com or training@fieldtriphealth.com, respectively.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.comhttps://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information  

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including interest in the training program, interest in the KAP Co-Op Program, uptake of the KAP Co-Op Program by therapists and patients, the timing and results of its research and development programs, approval of phase 1 human trials, if any, the risk that future clinical studies may not proceed as expected or may produce unfavorable results, the opening of additional clinics, the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
press@fieldtriphealth.com

Nick Opich / McKenna Miller
KCSA Strategic Communications
212-896-1206 / 347-487-6197
press@fieldtriphealth.com

Investor contacts:
Elizabeth Barker
KCSA Strategic Communications
212-896-1203
ebarker@kcsa.com

SOURCE Field Trip Health Ltd.

Wesana Health: Early Warning News Release

CHICAGO, Aug. 24, 2021 (GLOBE NEWSWIRE) — “Wesana Health Holdings Inc. (“Wesana” or “The Company”)(CSE:WESA; OTCBQB: WSNAF) would like to report that Chad Bronstein (the “Reporter”) of Chicago, Illinois, the Executive Chairman of Wesana Health Holdings Inc. (the “Company”), has filed an early warning report in accordance with National Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues related to the conversion of 3,900 Multiple Voting Shares of the Issuer into 195,000 Subordinate Voting Shares of the Issuer.

After the conversion of Multiple Voting Shares described above, the Reporter now holds 35,100 Multiple Voting Shares, representing 28.0% of the currently issued and outstanding Multiple Voting Shares, and 195,000 Subordinate Voting Shares, representing 1.5% of the outstanding Subordinate Voting Shares (assuming in the calculation of outstanding Subordinate Voting Shares, the conversion of all Multiple Voting Shares and Super Voting Shares, but no other securities).  If the Reporter were to convert all remaining Multiple Voting Shares held into Subordinate Voting Shares, the Reporter would hold 7.5% of then outstanding Subordinate Voting Shares (calculated on a partially diluted basis, assuming in the calculation of the Reporter’s holdings and the calculation of outstanding Subordinate Voting Shares, the conversion of all Multiple Voting Shares and Super Voting Shares, but no other securities).  The Multiple Voting Shares were converted pursuant to their terms for no further consideration.

The shares held or controlled by Mr. Bronstein are for investment purposes and are subject to an escrow time-based release schedule, as will be more particularly described in the early warning report. Mr. Bronstein currently has no plans or intentions that relate to, or would result in, any of the actions requiring disclosure under the early warning reporting provisions of applicable securities laws. In accordance with applicable securities laws, Mr. Bronstein may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments of the Company in the open market or otherwise, and reserves the right to dispose of any or all of such securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to such securities, the whole depending on market conditions, the business and prospects of the Company and other relevant factors, subject to applicable escrow restrictions.

A copy of the early warning report has been filed by Mr. Bronstein under the Company’s profile on SEDAR at www.sedar.com or may be obtained by contacting Nick Opich at 212-896-1206.

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972

For more information, please contact:
Media Contact:
Nick Opich / Annie Graf
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 786-390-2644


Primary Logo

Source: Wesana Health

TRYP THERAPEUTICS COMPLETES PSYCHOTHERAPY TRAINING FOR PHASE 2A STUDY AT THE UNIVERSITY OF FLORIDA

San Diego, California – August 24, 2021 – Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for over-eating disorders.  The training was conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients.

Tryp believes that both pharmaceutical and psychological processes will play a synergistic role to determine outcomes for TRP-8802, an oral formulation of synthetic psilocybin.  Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect.  Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming Phase 2a clinical trial for eating disorders conducted at the University of Florida with Jennifer Miller, M.D.  Following the administration of the drug, patients will also benefit from multiple integration sessions with the therapists.

Commenting on the recent psychotherapy training, Jesse Dallery, Ph.D., Director of the Behavioral Health and Technology Research Clinic and Professor in the Department of Psychology at the University of Florida, said, “Establishing definitive guidelines and training for the psychotherapy portion of psychedelic therapies is essential to minimizing variability and optimizing the patient experience.  I was thoroughly impressed with the rigor and scientific basis of the training provided by Fluence for our upcoming study with Tryp Therapeutics and look forward to initiating our work with patients later this year.”

Tryp Therapeutics, Fluence, and the University of Florida have collaborated to create a comprehensive training manual for the psychotherapy portion of Tryp’s psychedelic treatment regimen that will be adapted for subsequent clinical trials in fibromyalgia and other chronic pain indications.

“We continue to be amazed by the complexity of neural networks and the array of biological and behavioral factors that influence the healthy functioning of the brain and body,” said Jim Gilligan, Ph.D., President and Chief Science Officer of Tryp Therapeutics.  “Our partners at the University of Florida have shown tremendous commitment to the effective administration of psychotherapy for our upcoming Phase 2a clinical trial, and Fluence continues to be an exceptional partner for the design and implementation of this important component of our therapies.  The completion of this psychotherapy training marks a significant milestone for Tryp, as it remains an integral part of our novel treatment.”

 

About Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and over-eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience.  For more information, please visit www.tryptherapeutics.com.

Investor Inquiries:
Joe Green
Edison Group
investors@tryptherapeutics.com

Media Inquiries:

Joy Willis
Tryp Therapeutics
media@tryptherapeutics.com
1-833-811-8797

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Delic Announces Ben Westhoff, Award-Winning Investigative Reporter Specializing in Fentanyl to Speak at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, a revolutionary, two-day immersive edutainment experience for the world’s leading psychedelic and wellness thought and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, August 24, 2021 – Delic Holdings Corp. (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Ben Westhoff will serve as one of the headline speakers at Meet Delic the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, business and thought leaders.

Ben Westhoff is an award-winning investigative reporter who writes about culture, drugs, and poverty. His book Fentanyl, Inc.: How Rogue Chemists Created the Deadliest Wave of the Opioid Epidemic is the bombshell first book about the fentanyl epidemic, and he has advised officials at the top levels of government about the crisis. His previous book Original Gangstas is the definitive work on N.W.A., Tupac, and West Coast hip-hop. He came up in the alternative weeklies Riverfront Times and L.A. Weekly and has also written for The Atlantic, The Wall Street Journal, Rolling Stone, and the Guardian.

“I’ve spoken at conferences around the country, but have never been so excited as this one,” said Westhoff. “I hope to see you there!”

Westhoff ‘s keynote appearance, Fentanyl in our Drugs, will discuss how fentanyl isn’t just a problem for heroin users but how it is upending the entire recreational drug landscape. His presentation will show how fentanyl affects drug legalization prospects, dark web markets, geopolitics, and much more, and whether there’s any hope for ending the opioid crisis.

“Ben’s thought provoking journalism has exposed serious problems with the way we fight drug abuse and opens up the possibility of better treatment with far fewer side effects,” said Delic co-founder, Jackee Stang. “His objective take on the realm of treatments will be incredibly interesting and educational for the Meet Delic audience.”

Meet Delic will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic RadioDelic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute’s (“C-Path’s”) Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science.

C-Path ( www.c-path.org ) has multiple active consortia and programs that leverage knowledge

sharing to spur innovation. MindMed will participate in C-Path’s PRO Consortium, contributing to its collaborative framework for qualification of clinical outcome assessments (COAs) for use as efficacy endpoint measures in clinical trials.

“We welcome the opportunity to contribute our expertise in real-world data collection. Working with this industry leading effort gives us an opportunity to shape best practices in clinical evaluation and digital measurement,” said MindMed’s Chief Medical Officer Daniel Karlin, MD MA. “Technological advancement is allowing us to predict individual disease trajectories and outcomes, and enables us to build models of specific patterns and clusters of patient experiences. This progress paves the way for a new phase of personalized precision medicine.”

Stephen Joel Coons, PhD, Senior Vice President of C-Path’s COA Program, stated, “We are delighted to have MindMed join the PRO consortium, which further highlights MindMed’s commitment to patient-focused drug development. MindMed is blazing new trails in the treatment of a number of conditions that significantly impair human function and well-being, and we welcome its contributions to collaboratively advance  our understanding of the science underpinning the measurement of clinical benefit.”

MindMed’s goal is to help create more personalization in the pharmaceutical field that can allow for more accurate drug selection and drug combinations, precise dosage, timing and frequency of administration, and adjacent therapeutic interventions including psychotherapies and digital therapeutics.

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding MindMed’s role at C-Path, the ability to develop new approaches to advance innovation and regulatory science and MindMed’s success in its goals in the pharmaceutical field. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are  available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

arrow

PURE EXTRACTS TO HOST LIVE WEBCAST TO DISCUSS THE SIGNING OF THE DEFINITIVE AGREEMENT FOR THE MICHIGAN EXTRACTION JV AND TO PROVIDE A BUSINESS UPDATE

Vancouver, B.C., August 23, 2021 (GLOBE NEWSWIRE) – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, today announced that is plans to host a webinar on Wednesday, August 25, 2021, at 12:00 pm EST to discuss its latest Joint Venture in the United States and provide a general business update.

To access the live Webcast:

Join from a PC, Mac, iPad, iPhone, or Android device:

Please click this URL to join. https://us06web.zoom.us/j/87307043262?pwd=VnVEazlGdzdRYkRPbjM5UXRrZUFlQT09
Passcode: 907162

Or join by phone:

US: +1 253 215 8782
Canada: +1 778 907 2071
Webinar ID: 873 0704 3262
Passcode: 907162

International numbers available: https://us06web.zoom.us/u/kgWDovvTI

A video recording of the webcast will also be posted on the Company’s website approximately two hours following the live event.

Pure Extracts CEO, Ben Nikolaevsky, remarked “We are excited to be entering the Michigan extraction market, one of the fastest growing cannabis markets in the entire USA. Our JV partner is already selling to over 100 of the 400+ dispensaries in the State and as a result, we expect to drive significant revenues once we are fully operational in 2022. In Canada, we are now selling our products in 4 provinces including British Columbia (our home province), Alberta, Saskatchewan, and Ontario, with 2022 destined to be a year of rapid growth.” 

ON BEHALF OF THE BOARD

Ben Nikolaevsky
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)
Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/.

Or contact:

Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com  

Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding US expansion and the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

STATEMENT REGARDING UNITED STATES REGULATORY FRAMEWORK FOR CANNABIS

Pursuant to Pure Extracts’ joint venture with Golden Harvests, LLC, Pure Extracts expects to derive revenues from the cannabis industry in the State of Michigan in the United States, which industry is illegal under United States federal law. The joint venture is expected to be directly or indirectly engaged in the manufacture, possession, use, sale and distribution of cannabis in the medical and/or adult-use cannabis marketplace in the State of Michigan.

The United States federal government regulates drugs through the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. Under United States federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. The United States Food and Drug Administration has not approved cannabis as a safe and effective drug for any indication.

In the United States, cannabis is largely regulated at the state level. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal. Although certain states authorize medical and/or adult-use cannabis production and distribution by licensed or registered entities, under United States federal law, the possession, use, cultivation, and transfer of cannabis and any cannabis-related drug paraphernalia is illegal and any such acts are criminal acts under federal law. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and in case of conflict between federal and state law, the federal law shall apply.

There is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the United States Congress amends the CSA with respect to medical and/or adult-use cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that U.S. federal authorities may enforce current U.S. federal law. If the U.S. federal government begins to enforce U.S. federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing applicable state laws are repealed or curtailed, Pure Extracts’ business, results of operations, financial condition and prospects would be materially adversely affected. For these reasons, Pure Extracts’ operations in the United States cannabis market (through the joint venture) may subject Pure Extracts to heightened scrutiny by regulators, stock exchanges, clearing agencies and other Canadian and U.S. authorities and is subject to a number of risks, including those risks that are described in the Companies’ public filings profile on SEDAR at www.sedar.com .

To Pure Extract’s knowledge, no statement has been made by federal authorities or prosecutors regarding the risk of enforcement action with respect to state-sanctioned marijuana activities in the state of Michigan.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein

Wesana Health Highlights Recent Appointments to Board of Directors

Newest Additions to the Board Include Robert Koffman, MD, MPH and George Steinbrenner IV

TORONTO and CHICAGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF) is pleased to highlight the recent appointments of Robert Koffman, MD, MPH; Ian Burnstein; Mitch Kahn and George Michael Steinbrenner IV to its Board of Directors.

Chad Bronstein, Chairman of Wesana Health, commented, “Wesana is building a world-class board of directors to support its objective of becoming a global leader in the treatment of neurological health. The recent additions to the board will add a significant amount of strategic, scientific, investment and management guidance to drive overall company efforts related to the research and treatment of mental health conditions, including traumatic brain injury (TBI) and PTSD.”

Dr. Robert Koffman
A retired U.S. Navy Captain, Dr. Koffman has over 30 years of clinical, operational, and leadership experience as a naval medical officer. Appointed as the Navy’s first head of Combat and Operational Stress Control (COSC), Dr. Koffman advised the Navy Surgeon General as the Director for Psychological Health and directed the management of over $100 million in military spending to tackle the burgeoning problem of PTSD and blast related TBI. Dr. Koffman was also twice the Navy lead on the blue-ribbon panel authoring the DoD/VA Acute Stress Disorder (ASD) and Post Traumatic Stress Disorder (PTSD) Clinical Practice Guideline, and lead clinical operations at the premiere National Intrepid Center of Excellence (NICoE).

Dr. Koffman is currently serving as the Co-Chair of the Montgomery County Veteran Affairs Commission where he leads veteran suicide prevention efforts. Already conducting research on treatment resistant depression with psilocybin, he is slated to begin MDMA-Assisted Therapy under FDA Expanded Access at the Aquilino Cancer Center in Rockville, MD. Dr. Koffman obtained his doctorate from the University of Santo Tomas, his Master of Public Health from the Harvard School of Public Health and is a graduate from the Center for Psychedelic Treatment and Research at the California Institute of Integral Studies (CIIS).

On the appointment, Daniel Carcillo, Co-Founder and CEO of Wesana Health, said, “Dr. Koffman has been a passionate advocate for increasing veterans’ access to non-stigmatizing and non-traditional psychological services and integrative modalities. He has seen firsthand the devasting effects that PTSD and TBI can cause and will be a valuable resource to guide our research and treatment efforts on these fronts.”

On his appointment, Dr. Koffman said, “Wesana’s research has the ability to change lives—not just for wounded veterans—but for anyone dealing with the life changing consequences of TBI and trauma. I look forward to sharing my experience in operational medicine to guide this company as it continues to grow.”

Ian Burnstein
Mr. Burnstein brings a deep understanding of investment strategies, entrepreneurship, market knowledge, and philanthropy. He is the principal and co-founder of Equitable Advisors, a full-service advisory firm helping entrepreneurs execute on their business model, and serves as the Detroit Chair of Tiger 21, an investment group and peer membership organization for high-net-worth wealth creators. He is also the owner of Storage Pro Management, which oversees self-storage facilities in several states, and founded the Storage Business Owners Alliance, a buying cooperative group for self-storage owners.

Mr. Burnstein serves as the president of the board of the Dr. Gary Burnstein Community Health Clinic, which provides free health care in Pontiac, Detroit for more than 8,000 people annually. He earned his bachelor’s degree from the University of Michigan and his juris doctorate from the University of Detroit Mercy.

Mitchell Kahn
Mr. Kahn was the Co-Founder and Chief Executive Officer of Grassroots Cannabis, a private, vertically integrated, cannabis operation in the United States. Under Mr. Kahn’s tenure, Grassroots grew to over 1,100 team members across 11 states and received the approval of more than 60 regulatory licenses in the cannabis sector before it was purchased by Curaleaf Holdings Inc in July 2020. Prior to Grassroots Cannabis, Mitchell co-founded Frontline Real Estate Partners, a Chicago-based real estate investment and advisory company with expertise in the acquisition, development, management, disposition and leasing of commercial real estate properties throughout the United States. He actively serves as Chairman of Frontline Real Estate Partners and Fyllo Inc. He is also a director of both Curaleaf Holdings Inc. and Flower One Holdings Inc.

George Michael Steinbrenner IV
George is an entrepreneur and philanthropist having established a talent management agency, a business incubator and the George4 Foundation. He is also the Founder, President and Chief Executive Officer of Steinbrenner Racing which is involved with the NTT INDYCAR Series.

About Wesana
Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws with respect to the Company, including, but not limited to, information concerning the anticipated timing for receipt of results from the anxiety and depression study described above and the anticipated timing for commencement and conclusion of the Pivotal Study described above. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: research and development costs remaining consistent with budgets;; favorable operating conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labor stability;; the ability of the Company to be successful in its research and development initiatives; and the availability of third party service providers and other inputs for the Company’s operations. While the Company considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct.

Furthermore, such forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, financial position, performance or achievements of the Company to be materially different from any future plans, intentions, activities, results, financial position, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: research and development of drugs targeting the central nervous system being particularly difficult; delivering data from ongoing pre-clinical and clinical studies; competition from other biotechnology and pharmaceutical companies; reliance on third parties to plan, conduct and monitor preclinical studies and clinical trials; negative results from pre-clinical and clinical trials or studies of others; unfavorable publicity or consumer perception; not achieving publicly announced milestones; reliance on the capabilities and experience of key executives and scientists; disruptions due to acquisitions or collaborations; risk of product liability claims; COVID-19; litigation; conflicts of interest; limited operating history; exposure to the fluctuation of foreign exchange rates; ability to protect intellectual property; changes in patent law; requirements to share intellectual property with service providers; general economic, market and business conditions, other risks factors including those found in the Company’s Listing Statement dated May 6, 2021 filed on SEDAR at www.sedar.com and discussed in the Company’s other public filings available on SEDAR. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is provided and made as of the date of this news release and the Company does not undertake any obligation to revise or update any forward-looking information other than as required by applicable law.

For more information, please contact:

Media Contact:
Nick Opich / Annie Graf
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 786-390-2644

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972


Primary Logo

Source: Wesana Health

PURE EXTRACTS AND GROWN ROGUE FORM JOINT VENTURE TO EXPAND PRODUCT OFFERING IN MICHIGAN

Vancouver, British Columbia and Medford, Oregon, August 19, 2021 – Pure Extracts Technologies Corp. (“Pure Extracts”) (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) today announced the signing of a Definitive Agreement for a joint venture between its Michigan subsidiary, Pure Extracts USA Inc., and Grown Rogue International Inc.’s (“Grown Rogue”) (CSE: GRIN) (OTC: GRUSF) Michigan subsidiary, Golden Harvests, LLC (“Golden”) to expand Grown Rogue’s product offering and bring Pure Extracts’ portfolio of products to Michigan. Grown Rogue is a multi-state operating (MSO) cannabis company with operations and assets in Oregon and Michigan.

In addition to Pure Extracts’ Pure Pulls and Pure Chews, Grown Rogue will be adding to their Michigan product portfolio to include concentrates and cartridges to complement their award-winning flower and their proprietary, 3.5gram, nitrogen sealed flower jars already one of the leading flower brands in the state.

“We are excited to expand our product offering in Michigan to include new products that doubles our addressable market in a top 5 cannabis state,” said Obie Strickler, CEO of Grown Rogue. “We have consumers that actively seek out the processors who purchase our trim for their own products so this joint venture will help fulfill the increasing demand for Grown Rogue’s high quality products in the state of Michigan, increase the strong brand equity our team is building, and capture additional margin for the company.”

Pure Extracts is a plant-based extraction company focused on cannabis and hemp based out of British Columbia, Canada. Pure Extracts will provide a mix of equipment, cash, and extraction expertise to the venture, which will allow the partners to rapidly scale-up to meet the rising demand for processed products throughout the state.

The joint venture plans to build-out 2,600 square feet of existing space in the 80,000 sq ft facility in Bay City. The JV has the ability to produce Grown Rogue branded concentrates, cartridges, edibles and tinctures as well as similar items under Pure Extracts’ brand. The JV will consider building dedicated greenhouse production to provide cheaper processing input for house brands and available white label opportunities.

“We are excited to be teaming up with Grown Rogue, renowned cultivators who have already sold their cannabis products to over 100 dispensaries throughout Michigan, a state where cannabis sales reached a record $171 million in July of this year, up 56% from a year ago,” said Ben Nikolaevsky, CEO of Pure Extracts. “Establishing Pure Extracts’ brands in the United States, the world’s largest and most important cannabis market, is an important milestone for our company.”

About Grown Rogue

Grown Rogue International (CSE: GRIN | OTC: GRUSF) is a vertically integrated, multi-state Cannabis family of brands on a mission to inspire consumers to “enhance experiences” through cannabis. We have combined an expert management team, award winning grow team, state of the art indoor and outdoor manufacturing facilities, and consumer insight based product categorization, to create innovative products thoughtfully curated from “seed to experience.”  The Grown Rogue family of products include sungrown and indoor premium flower, along with nitro sealed indoor and sungrown pre-rolls and jars.

About Pure Extracts

Pure Extracts Technology Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020 and its Sales Amendment on July 19, 2021. The company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

FORWARD-LOOKING STATEMENTS

This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Grown Rogue and Pure Extracts       (“the Companies”) with respect to future business activities. Forward‐ looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Companies (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Companies into Michigan and securing applicable regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward‐looking information is not based on historical facts but instead reflect the Companies’ management’s expectations, estimates or projections concerning the business of the Companies’ future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Companies believe that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Companies to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Companies operate in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Companies’ public disclosure documents filed on www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Companies have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Companies do not intend, and do not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

For further information on Grown Rogue International please visit www.grownrogue.com or contact:

Obie Strickler
Chief Executive Officer
obie@grownrogue.com
Investor Relations Desk Inquiries
invest@grownrogue.com
(458) 226-2100

For further information on Pure Extracts please visit www.pureextractscorp.com/ or contact:

Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com

SAFE HARBOR STATEMENT

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Companies, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Companies’ financial condition or results of operations; (iii) the Companies’ growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Companies’ ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in Grown Rogue’s Form 20-F and 6-K filings with the Securities and Exchange Commission. 

STATEMENT REGARDING UNITED STATES REGULATORY FRAMEWORK FOR CANNABIS

Pursuant to Pure Extracts’ joint venture with Golden Harvests, LLC, Pure Extracts expects to derive revenues from the cannabis industry in the State of Michigan in the United States, which industry is illegal under United States federal law. The joint venture is expected to be directly or indirectly engaged in the manufacture, possession, use, sale and distribution of cannabis in the medical and/or adult-use cannabis marketplace in the State of Michigan.

The United States federal government regulates drugs through the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. Under United States federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. The United States Food and Drug Administration has not approved cannabis as a safe and effective drug for any indication.  

In the United States, cannabis is largely regulated at the state level. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal. Although certain states authorize medical and/or adult-use cannabis production and distribution by licensed or registered entities, under United States federal law, the possession, use, cultivation, and transfer of cannabis and any cannabis-related drug paraphernalia is illegal and any such acts are criminal acts under federal law. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and in case of conflict between federal and state law, the federal law shall apply.

There is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the United States Congress amends the CSA with respect to medical and/or adult-use cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that U.S. federal authorities may enforce current U.S. federal law. If the U.S. federal government begins to enforce U.S. federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing applicable state laws are repealed or curtailed, Pure Extracts’ business, results of operations, financial condition and prospects would be materially adversely affected. For these reasons, Pure Extracts’ operations in the United States cannabis market (through the joint venture) may subject Pure Extracts to heightened scrutiny by regulators, stock exchanges, clearing agencies and other Canadian and U.S. authorities and is subject to a number of risks, including those risks that are described in the Companies’ public filings profile on SEDAR at www.sedar.com .

To Pure Extracts’s knowledge, no statement has been made by federal authorities or prosecutors regarding the risk of enforcement action with respect to state-sanctioned marijuana activities in the state of Michigan.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

 

Dr. Southey and Dr. Zarrebini Join M2Bio Sciences and Establish M2Bio Blockchain Research and Technology Group

CAPE TOWN, SA / ACCESSWIRE / August 19, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:

WUHAN GENERAL GROUP, in partnership with Catena. MBA, has formed the M2Bio Blockchain Research and Technology Group. The company is committed to its long-term vision and mission to improve quality of life through the use of robust science and emerging technologies. The implementation of blockchain solutions (widely accepted as adding significant traceability and data integrity) will challenge the existing functional-emotional orientation of the industry, and aim to reconstruct market boundaries and create new market opportunities.

The company is equally committed to value creation for local communities and has recently received an endorsement from the Lesotho government to develop blockchain projects that support these endeavours.

In its first phases, a seed-to-sale provenance tool for CBD and related products enables M2Bio and the Kingdom of Lesotho to bring trusted bioceutical to the global market. That said, the Research Group has aspirations that are far more wide-reaching.

With an already broad range of retail products, M2Bio’s blockchain solution is perfectly positioned to enhance existing supply chains for chocolate, coffee, tea, olive oils, honey and the myriad of hemp and mycelium related items which are derived from their manufacturing processes.

Additionally, as an organization focused on sustainability and biodegradable packaging, M2Bio will support both supply and consumption chains to provide traceability throughout the circular economy. M2Bio has recently launched a range of NFT’s which unlocked ownership of the world’s first fully compostable surf board.

The Blockchain Research and Technology Group is working with leading edge technologies and global leaders to provide a modular and widely applicable solution which can cut across all industry supply chains.

The new division is headed up by:

Dr. Stewart Southey, a senior partner at Catena, received his MBBCh from The University of the Witwatersrand and completed his postgraduate Anesthesiology training in the UK where he was awarded Fellowship of the Royal College of Anesthetists. Although still practicing as a part time clinician, his passion for innovation in healthcare led him to graduate with an MBA and subsequently an MSc (cum laude) in Digital Currencies and Blockchain. Much of his work focuses on the use of blockchain technology in healthcare.

Dr. Mehran Zarrebini, a senior partner at Catena, is a Chemical Engineer by training, with a PhD in Chemical Engineering from the University of Cambridge, UK. Mehran runs the largest rubber tire recycling company in Africa (based in Kwa-Zulu Natal), and is a global leader in the Circular Economy arena. He has an MBA (cum laude) from the University of Stellenbosch Business School and graduated alongside Dr Southey with an MSc in Digital Currencies and Blockchain.

Their combined expertise makes them perfect candidates to develop a robust supply chain solution for Wuhan General Group that shifts the focus from competing within to looking across defined industry boundaries. Catena. MBA has worked on projects in the pharmaceutical supply chain and is heavily committed to sustainability and circular economy solutions across multiple sectors. Their recent work with the World Health Organization further supports their passion for improving global health and quality of life.

“Catena and M2Bio are highly aligned in tackling some of these critical issues. There is great synergy in what we are all trying to achieve, and the partnership just makes perfect sense for us”, said Dr Zarrebini.

The team will be working closely with all relevant M2Bio partners along the supply chain to create value for participants in the network. It is anticipated that the blockchain solution will further enhance the legitimacy of M2Bio’s psilocybin-related research. Dr. Southey admits to being “incredibly thrilled to be a part of this scientific work, particularly as it relates to the potential benefits for patients with mental health and end-of-life issues. There are numerous trials showing promise in the treatment of Depression, Anxiety and Posttraumatic-Stress-Disorders. It would be immensely gratifying to help find trusted solutions for these patients”.

And finally, Wuhan CEO Jeff Robinson added: “It’s a real honour to have Stewart and Mehran as part of the team. They are unmistakably brilliant thought and execution leaders.”

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC PINK:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.

Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs

TORONTO, CANADA – August 19, 2021 – Cybin Inc.(NEO:CYBN) (NYSEAMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed two additional international patent applications that bring the potential to obtain patent coverage in 153 countries for each of the patent applications.

The application, governed by the Patent Cooperation Treaty (“PCT”), grants the Company the right to file future national applications into treaty member jurisdictions, including important potential markets for the Company. The PCTs claim a library of phenethylamine and derivative drug development candidates and methods of use.

One of the PCT applications claims a group of proprietary compounds identified by the Company’s research data as being important for further evaluation toward selection as potential therapeutics. The other PCT application includes claims and disclosures toward several other proprietary novel psychedelic compounds, including compounds with positive research data, meeting the Company’s internal research metrics.  The Company believes these applications will further strengthen the CYB005 program, directed to therapy resistant psychiatric disorders, and provide compositions for further evaluation in additional future research programs.

The Company continues to execute upon its three-pillar drug development strategy to create: (a) a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; (b) efficient drug delivery to enhance dosing control; and (c) a potential novel treatment regimen. These PCT applications are intended to provide broad international patent protection of key intellectual property in support of the Company’s strategic objectives.

The Company’s current indications include major depressive disorder (CYB001), alcohol use disorder (CYB003) and anxiety disorders (CYB004). In addition, two programs in the research phase (CYB005 and CYB006) involved synthesis and testing of more than 50 novel compounds coupled with extensive in-vitro and in-vivo pharmacokinetic, receptor binding, behavioral and safety evaluations.

“Cybin is dedicated to finding treatments for therapy resistant psychiatric indications as we believe these will provide patients and their medical providers with new avenues to address this significant unmet need.  We appreciate the continued dedication of our team to identify and progress our research phase programs toward pre-clinical evaluation,” said Doug Drysdale, CEO.

About Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s new strategic brand messaging campaign, and psychedelic drug development programs to potentially treat mental health disorders. There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

Investor Contacts: 

Tim Regan/Scott Eckstein

KCSA Strategic Communications

Cybin@kcsa.com

 

Lisa M. Wilson

In-Site Communications, Inc.

lwilson@insitecony.com

 

Media Contact:

John Kanakis

Cybin Inc.

John@cybin.com